Takeda Pharmaceutical (TAK) Non-Current Deferred Tax Liability (2017 - 2026)

Takeda Pharmaceutical has reported Non-Current Deferred Tax Liability for 10 years, with the latest figure at $169.6 million in Q2 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 26.76% year-over-year to $169.6 million in Q2 2026; TTM through Jun 2026 was $169.6 million, a 26.76% decrease from a year earlier, with the FY2026 full-year figure at $170.9 million, down 25.94% from the prior year.
• Non-Current Deferred Tax Liability was $169.6 million for Q2 2026 at Takeda Pharmaceutical, down from $170.9 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $3.9 billion in Q1 2022, with the low at $169.6 million in Q2 2026.
• Average Non-Current Deferred Tax Liability over 5 years is $1.3 billion, with a median of $562.2 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Non-Current Deferred Tax Liability plunged 81.87% in 2024, then retreated 17.97% in 2025.
• Over 5 years, Non-Current Deferred Tax Liability stood at $2.8 billion in 2022, then sank by 67.29% to $900.0 million in 2023, then plunged by 72.47% to $247.8 million in 2024, then decreased by 17.97% to $203.3 million in 2025, then decreased by 16.54% to $169.6 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $169.6 million (Q2 2026), $170.9 million (Q1 2026), and $203.3 million (Q4 2025), per Business Quant data.